New biologic drugs aim to tame rare lung allergy in severe asthma patients

NCT ID NCT07362693

First seen Jan 23, 2026 · Last updated May 14, 2026 · Updated 15 times

Summary

This study looks at whether biologic drugs can safely reduce flare-ups in people with allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common mold. About 50 adults with severe asthma and a history of asthma attacks will receive biologic treatment and be followed for one year. The main goal is to see if these drugs lower the number of acute episodes and the need for steroids.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China

    RECRUITING

    Jinan, Shandong, 250014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.